Vanda Pharmaceuticals Inc.

VNDA Net selling

CIK 0001347178 #3500 in the set updated 19 Sep 2026

Bought (120 mo)

$513.64K

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$51.31M

$0.00 on a plan · $16.46M straight out of an exercise

Sold at will

$34.84M

118 of 151 sales

Net

−$50.79M

−$34.33M against sales at will

By person

22 insiders · 169 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Polymeropoulos Mihael Hristos

President and CEO

$504.86K (14)

$21.77M (34) scheduled

−$21.26M

2,704,496

4.47%

$22.36M

+212.6%

Flynn James E

10% owner

—

$19.27M (9)

−$19.27M

4,328,344

7.16%

$35.78M

−21.2%

Birznieks Gunther

SVP, Business Development

—

$2.02M (19)

−$2.02M

494,197

0.8174%

$4.08M

+289.3%

Williams Timothy

SVP & General Counsel

—

$1.55M (19)

−$1.55M

377,450

0.6243%

$3.12M

—

Jones Aranthan II

Chief Corp. Affairs Officer

—

$1.43M (7) scheduled

−$1.43M

81,980

0.1356%

$677.64K

+36.6%

Kelly James Patrick

EVP & Chief Financial Officer

—

$1.16M (11)

−$1.16M

186,869

0.3091%

$1.54M

+131.4%

Moran Kevin Patrick

SVP, CFO & Treasurer

$8.78K (1)

$1.06M (16)

−$1.05M

412,015

0.6814%

$3.41M

+571.2%

Wijkstrom Joakim

SVP, Chief Marketing Officer

—

$706.47K (11)

−$706.47K

333,469

0.5515%

$2.76M

—

Mitchell Stephen Ray

Director

—

$540.03K (6) scheduled

−$540.03K

112,846

0.1866%

$932.77K

+56,323%

DUGAN RICHARD W

Director

—

$505.27K (4) scheduled

−$505.27K

219,054

0.3623%

$1.81M

+3,696%

Gulino Richard L.

SVP, General Counsel & Sec.

—

$395.13K (3) scheduled

−$395.13K

115,073

0.1903%

$951.18K

+187.7%

Watkins Thomas

Director

—

$282.92K (3) scheduled

−$282.92K

63,064

0.1043%

$521.28K

—

Baroldi Paolo

SVP & Chief Medical Officer

—

$252.78K (1) scheduled

−$252.78K

54,365

0.0899%

$449.38K

+574.1%

Honore Tage

Director

—

$240.90K (1)

−$240.90K

135,069

0.2234%

$1.12M

—

Reverberi Gian Piero

SVP & Chief Commercial Officer

—

$81.00K (6)

−$81.00K

165,384

0.2735%

$1.37M

+313.5%

Chrousos Phaedra

Director

—

$40.13K (1)

−$40.13K

164,950

0.2728%

$1.36M

—

Ward Anne Sempowski

Director

—

—

—

160,667

0.2657%

$1.33M

—

McGuire Daniel Patrick

SVP, GC and Secretary

—

—

—

109,982

0.1819%

$909.10K

+266.8%

Duncan Charles Cliff

Director

—

—

—

98,701

0.1632%

$815.85K

—

COLA MICHAEL F

Director

—

—

—

15,000

0.0248%

$123.99K

—

MILANO VINCENT

Director

—

—

—

10,000

0.0165%

$82.66K

—

BATE KENNETH

Director

—

—

—

5,000

0.0083%

$41.33K

—

Individual transactions

3

Insider

Date

Role

Action

Shares

Price

Amount

Birznieks Gunther

26 Aug 2022

SVP, Business Development

Exercised, kept

1,250

$3.12

$3.90K

Watkins Thomas

3 May 2018

Director

Exercised, kept

15,000

$4.98

$74.70K

DUGAN RICHARD W

19 Mar 2018

Director

Exercised, kept

15,000

$4.98

$74.70K

Show all 169 transactions →

What was left out

Form 4 filings counted 219

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 2

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 33

Sales at will 118

Transactions with no price 0

Shares from compensation/vesting 7,423,904

Sales filed before the plan box existed 93

History held since 19 Sep 2016